FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO Post published:May 30, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON Post published:May 17, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Post published:May 13, 2023 Post category:Press Release
FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE Post published:May 8, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES SPRING 2023 EVENT AND MEDIA APPEARANCES Post published:April 25, 2023 Post category:Press Release
FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES Post published:April 11, 2023 Post category:Press Release
FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Post published:April 1, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING PSILOCYBIN FOR METHAMPHETAMINE USE DISORDER Post published:March 15, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Post published:February 14, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN Post published:January 20, 2023 Post category:Press Release